Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis

doi 10.31128/afp-09-17-4348

Full Text

Abstract

Available in

Date

April 1, 2018

Authors

Annabel G Markey

Judith C Killen

Publisher

The Royal Australian College of General Practitioners

Related search

Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis

European Scientific Journal ESJ

Spanish

Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through?

English

Sodium-Glucose Co-Transporter Type-2 Inhibitors: Pharmacology and Peri-Operative Considerations

English

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes—a Dangerous Ally

US Endocrinology

English

Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through? A Reply

English

Early Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Type 2 Diabetes: Study Based on Continuous Glucose Monitoring

Diabetology and Metabolic Syndrome

Internal Medicine

English

Pdb1 - Acute Renal Outcomes With Sodium Glucose Co-Transporter 2 Inhibitors- Real World Data Analysis

Value in Health

Occupational Health

English

Sodium-Glucose Co-Transporter 2 Inhibitors in the Peri-Operative Period: A Warning to All Clinicians

BJU International

English

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin

Journal of Investigative Medicine High Impact Case Reports

Safety Research

English